CL2019001726A1 - Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios. - Google Patents
Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.Info
- Publication number
- CL2019001726A1 CL2019001726A1 CL2019001726A CL2019001726A CL2019001726A1 CL 2019001726 A1 CL2019001726 A1 CL 2019001726A1 CL 2019001726 A CL2019001726 A CL 2019001726A CL 2019001726 A CL2019001726 A CL 2019001726A CL 2019001726 A1 CL2019001726 A1 CL 2019001726A1
- Authority
- CL
- Chile
- Prior art keywords
- task
- respiratory disorders
- treatment
- pharmaceutical administration
- forms containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE SOLICITUD SE REFIERE A NUEVAS FORMAS DE ADMINISTRACIÓN FARMACÉUTICA QUE CONTIENEN INHIBIDORES POTENTES Y SELECTIVOS DE LOS CANALES TASK-1 Y/O TASK-3 Y A SU USO PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS RESPIRATORIOS, INCLUYENDO TRASTORNOS RESPIRATORIOS RELACIONADOS CON EL SUEÑO, TALES COMO LA APNEA OBSTRUCTIVA Y LA APNEA CENTRAL DEL SUEÑO Y EL RONQUIDO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16205688.1A EP3338764A1 (de) | 2016-12-21 | 2016-12-21 | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
EP17157805 | 2017-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001726A1 true CL2019001726A1 (es) | 2019-11-29 |
Family
ID=60857052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001726A CL2019001726A1 (es) | 2016-12-21 | 2019-06-20 | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20200093737A1 (es) |
EP (1) | EP3558380A1 (es) |
JP (1) | JP2020502215A (es) |
KR (1) | KR20190099245A (es) |
CN (1) | CN110290809A (es) |
AU (1) | AU2017379245A1 (es) |
BR (1) | BR112019012836A2 (es) |
CA (1) | CA3047426A1 (es) |
CL (1) | CL2019001726A1 (es) |
CO (1) | CO2019006642A2 (es) |
CR (1) | CR20190299A (es) |
CU (1) | CU20190063A7 (es) |
DO (1) | DOP2019000172A (es) |
EC (1) | ECSP19044577A (es) |
IL (1) | IL267503A (es) |
JO (1) | JOP20190148A1 (es) |
MA (1) | MA47074A (es) |
MX (1) | MX2019007619A (es) |
PE (1) | PE20191240A1 (es) |
PH (1) | PH12019501458A1 (es) |
TW (1) | TW201834653A (es) |
UY (1) | UY37541A (es) |
WO (1) | WO2018114501A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20207104B (en) | 2015-12-10 | 2020-05-11 | Bayer Pharma AG | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為malt1抑制劑之吡唑衍生物 |
JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
ES2966457T3 (es) | 2018-06-18 | 2024-04-22 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
JOP20210121A1 (ar) * | 2018-11-27 | 2023-01-30 | Bayer Ag | عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة task-1 و task-3، واستخدامها في علاج اضطراب التنفس |
CN115835864A (zh) * | 2020-07-01 | 2023-03-21 | 国立癌症中心 | 包含3-酮脂酰辅酶a硫解酶抑制剂以及肉碱酰基肉碱载体抑制剂的用于预防或治疗癌症的药物组合物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
NZ572231A (en) * | 2006-04-27 | 2010-12-24 | Sanofi Aventis Deutschland | Inhibitors of the task-1 and task-3 ion channel |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
MX2013000198A (es) | 2010-07-09 | 2013-01-28 | Bayer Ip Gmbh | Pirimidinadas y triazinas condensadas y su uso. |
US9132243B2 (en) | 2010-07-23 | 2015-09-15 | Tannermedico A/S | Method of administering a substance to the throat |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
CN103877288B (zh) * | 2014-04-16 | 2016-01-20 | 广西信业生物技术有限公司 | 一种壳聚糖鼻咽生物医用膜及其制备方法 |
-
2017
- 2017-06-16 JO JOP/2019/0148A patent/JOP20190148A1/ar unknown
- 2017-12-13 MX MX2019007619A patent/MX2019007619A/es unknown
- 2017-12-13 CA CA3047426A patent/CA3047426A1/en not_active Abandoned
- 2017-12-13 CN CN201780086896.1A patent/CN110290809A/zh active Pending
- 2017-12-13 EP EP17822216.2A patent/EP3558380A1/de not_active Withdrawn
- 2017-12-13 CU CU2019000063A patent/CU20190063A7/es unknown
- 2017-12-13 JP JP2019533535A patent/JP2020502215A/ja active Pending
- 2017-12-13 PE PE2019001285A patent/PE20191240A1/es unknown
- 2017-12-13 CR CR20190299A patent/CR20190299A/es unknown
- 2017-12-13 BR BR112019012836A patent/BR112019012836A2/pt not_active Application Discontinuation
- 2017-12-13 KR KR1020197020701A patent/KR20190099245A/ko unknown
- 2017-12-13 MA MA047074A patent/MA47074A/fr unknown
- 2017-12-13 WO PCT/EP2017/082542 patent/WO2018114501A1/de unknown
- 2017-12-13 US US16/472,116 patent/US20200093737A1/en not_active Abandoned
- 2017-12-13 AU AU2017379245A patent/AU2017379245A1/en not_active Abandoned
- 2017-12-19 TW TW106144527A patent/TW201834653A/zh unknown
- 2017-12-21 UY UY0001037541A patent/UY37541A/es not_active Application Discontinuation
-
2019
- 2019-06-19 DO DO2019000172A patent/DOP2019000172A/es unknown
- 2019-06-19 IL IL267503A patent/IL267503A/en unknown
- 2019-06-20 CL CL2019001726A patent/CL2019001726A1/es unknown
- 2019-06-21 CO CONC2019/0006642A patent/CO2019006642A2/es unknown
- 2019-06-21 PH PH12019501458A patent/PH12019501458A1/en unknown
- 2019-06-21 EC ECSENADI201944577A patent/ECSP19044577A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018114501A1 (de) | 2018-06-28 |
EP3558380A1 (de) | 2019-10-30 |
PH12019501458A1 (en) | 2020-06-01 |
MX2019007619A (es) | 2019-09-06 |
CR20190299A (es) | 2019-09-04 |
PE20191240A1 (es) | 2019-09-16 |
MA47074A (fr) | 2021-04-14 |
CO2019006642A2 (es) | 2019-09-18 |
US20200093737A1 (en) | 2020-03-26 |
CU20190063A7 (es) | 2020-02-04 |
ECSP19044577A (es) | 2019-06-30 |
CA3047426A1 (en) | 2018-06-28 |
CN110290809A (zh) | 2019-09-27 |
UY37541A (es) | 2018-07-31 |
JP2020502215A (ja) | 2020-01-23 |
TW201834653A (zh) | 2018-10-01 |
BR112019012836A2 (pt) | 2019-12-17 |
IL267503A (en) | 2019-08-29 |
KR20190099245A (ko) | 2019-08-26 |
JOP20190148A1 (ar) | 2019-06-18 |
DOP2019000172A (es) | 2019-07-15 |
AU2017379245A1 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001727A1 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios. | |
CL2019001726A1 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios. | |
ECSP18043573A (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño | |
CL2019000129A1 (es) | Compuestos diazaheterobicíclicos sustituidos y su uso. | |
BR112016023815A2 (pt) | composições tópicas para o alívio da dor, produção e uso | |
DOP2017000087A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
CR20160290A (es) | Inhibidores tetracíclicos de autotaxina | |
MX2016014696A (es) | Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica. | |
DOP2021000105A (es) | Proceso para la producción de formas farmacéuticas que contienen inhibidores de los canales task1 y task3 y su uso para la terapia de trastornos respiratorios | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CO2018004803A2 (es) | Compuestos oxa-diazaspiro que tienen actividad contra el dolor | |
AR110417A1 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
EA201991538A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания | |
CL2015003211A1 (es) | Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
EA201991540A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания | |
DOP2015000290A (es) | Benzoxazoles sustituidos | |
UY35443A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina | |
ES2532749R1 (es) | Péptidos bloqueantes de termorreceptores y sus usos |